Matan C Dabora

Harvard Business School - Boston / United States

Medical and Health Sciences / Pharmacy & Pharmaceutical Sciences

AD Scientific Index ID: 4621145

Registration, Add Profile,
Premium Membership

Print Your Certificate

Matan C Dabora's MOST POPULAR ARTICLES

1-) Bamlanivimab plus etesevimab in mild or moderate Covid-19M Dougan, A Nirula, M Azizad, B Mocherla, RL Gottlieb, P Chen, C Hebert, ...New England Journal of Medicine 385 (15), 1382-1392, 20216992021

2-) Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living FacilitiesMD Myron S. Cohen, PD Ajay Nirula, MD, MD Mark J. Mulligan, ...JAMA, 20212132021

3-) A randomized, placebo-controlled clinical trial of bamlanivimab and etesevimab together in high-risk ambulatory patients with COVID-19 and validation of the prognostic value of …M Dougan, M Azizad, B Mocherla, RL Gottlieb, P Chen, C Hebert, R Perry, ...Clinical Infectious Diseases 75 (1), e440-e449, 2022692022

4-) β-alanine supplementation improves tactical performance but not cognitive function in combat soldiersJR Hoffman, G Landau, JR Stout, M Dabora, DS Moran, N Sharvit, ...Journal of the International Society of Sports Nutrition 11, 1-8, 2014592014

5-) Financing and distribution of pharmaceuticals in the United StatesMC Dabora, N Turaga, KA SchulmanJama 318 (1), 21-22, 2017472017

ARTICLES

Add your articles